BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 16934800)

  • 1. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
    Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
    Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.
    Leng RP; Lin Y; Ma W; Wu H; Lemmers B; Chung S; Parant JM; Lozano G; Hakem R; Benchimol S
    Cell; 2003 Mar; 112(6):779-91. PubMed ID: 12654245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
    Xu C; Fan CD; Wang X
    Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
    Duan W; Gao L; Druhan LJ; Zhu WG; Morrison C; Otterson GA; Villalona-Calero MA
    J Natl Cancer Inst; 2004 Nov; 96(22):1718-21. PubMed ID: 15547185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 ubiquitination: Mdm2 and beyond.
    Brooks CL; Gu W
    Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
    Min SH; Kim DM; Heo YS; Kim HM; Kim IC; Yoo OJ
    Life Sci; 2010 Jan; 86(1-2):66-72. PubMed ID: 19945467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
    Shloush J; Vlassov JE; Engson I; Duan S; Saridakis V; Dhe-Paganon S; Raught B; Sheng Y; Arrowsmith CH
    J Biol Chem; 2011 Feb; 286(6):4796-808. PubMed ID: 21084285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.
    Corcoran CA; Montalbano J; Sun H; He Q; Huang Y; Sheikh MS
    J Biol Chem; 2009 Aug; 284(33):21955-21970. PubMed ID: 19483087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
    Hattori T; Isobe T; Abe K; Kikuchi H; Kitagawa K; Oda T; Uchida C; Kitagawa M
    Cancer Res; 2007 Nov; 67(22):10789-95. PubMed ID: 18006823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
    Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
    FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel oncoprotein Pirh2: rising from the shadow of MDM2.
    Wang Z; Yang B; Dong L; Peng B; He X; Liu W
    Cancer Sci; 2011 May; 102(5):909-17. PubMed ID: 21284766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest.
    Corcoran CA; Huang Y; Sheikh MS
    Cancer Biol Ther; 2004 Aug; 3(8):721-5. PubMed ID: 15280670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage.
    Magrini R; Russo D; Fronza G; Inga A; Menichini P
    J Cell Biochem; 2007 Apr; 100(5):1276-87. PubMed ID: 17063487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
    Arriola EL; Lopez AR; Chresta CM
    Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2.
    García-Cano J; Sánchez-Tena S; Sala-Gaston J; Figueras A; Viñals F; Bartrons R; Ventura F; Rosa JL
    Mol Oncol; 2020 Jan; 14(1):69-86. PubMed ID: 31665549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
    Swaroop M; Sun Y
    Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golgi-SNARE GS28 potentiates cisplatin-induced apoptosis by forming GS28-MDM2-p53 complexes and by preventing the ubiquitination and degradation of p53.
    Sun NK; Huang SL; Chien KY; Chao CC
    Biochem J; 2012 Jun; 444(2):303-14. PubMed ID: 22397410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIAD1 is negatively regulated by the MDM2 E3 ligase.
    Bae S; Jung JH; An IS; Kim OY; Lee MJ; Lee JH; Park IC; Lee SJ; An S
    Oncol Rep; 2012 Nov; 28(5):1924-8. PubMed ID: 22940738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.